| Acromegaly

Somavert vs Somatuline Depot

Side-by-side clinical, coverage, and cost comparison for acromegaly.

Deep comparison between: Somavert vs Somatuline Depot with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsSomatuline Depot has a higher rate of injection site reactions vs Somavert based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Somatuline Depot but not Somavert, including UnitedHealthcare

Category

Somavert

Somatuline Depot

At A Glance

RouteSC injection

FrequencyDaily

ClassGH receptor antagonist

RouteSC injection

FrequencyEvery 4 weeks

ClassSomatostatin analog

Indications

Acromegaly

Acromegaly
Gastro-enteropancreatic neuroendocrine tumor
Malignant Carcinoid Syndrome

Dosing

Acromegaly 40 mg SC loading dose under physician supervision, then 10 mg SC once daily starting the next day; titrate in 5 mg increments or decrements every 4-6 weeks to normalize IGF-1; maintenance range 10-30 mg SC once daily.

Acromegaly 90 mg deep SC injection every 4 weeks for 3 months; adjust thereafter to 60-120 mg every 4 weeks based on GH and/or IGF-1 levels; controlled patients may extend to 120 mg every 6 or 8 weeks. Starting dose reduced to 60 mg every 4 weeks in moderate or severe renal or hepatic impairment.

Gastro-enteropancreatic neuroendocrine tumor, Malignant Carcinoid Syndrome 120 mg deep SC injection every 4 weeks; if already receiving treatment for GEP-NET, do not administer an additional dose for carcinoid syndrome.

Contraindications

—

History of hypersensitivity to lanreotide (including angioedema and anaphylaxis)

Drug Interactions

968View drug interactions

930View drug interactions

Adverse Reactions

Most common Infection, pain, nausea, diarrhea, abnormal liver function tests, flu syndrome, injection site reaction, dizziness

Serious Transaminase elevations >10x ULN, hepatotoxicity, lipohypertrophy, systemic hypersensitivity reactions

Postmarketing Anaphylactic reactions, laryngospasm, angioedema, rash, erythema, pruritus, urticaria

Most common (>5%) Diarrhea, abdominal pain, nausea, constipation, flatulence, vomiting, loose stools, cholelithiasis, injection site reactions, musculoskeletal pain, arthralgia, headache, hyperglycemia, hypertension, dizziness

Serious Cholelithiasis and complications of cholelithiasis, hyperglycemia and hypoglycemia, cardiovascular abnormalities, thyroid function abnormalities, steatorrhea and malabsorption of dietary fats

Postmarketing Pancreatic exocrine insufficiency, steatorrhea, cholecystitis, cholangitis, pancreatitis, angioedema, anaphylaxis, injection site abscess

Pharmacology

GH receptor antagonist; pegvisomant selectively binds to growth hormone (GH) receptors on cell surfaces, blocking endogenous GH binding and interfering with GH signal transduction, resulting in decreased serum concentrations of IGF-1, free IGF-1, ALS, and IGFBP-3.

Lanreotide is a synthetic octapeptide analog of natural somatostatin with high binding affinity for somatostatin receptors SSTR2 and SSTR5; it inhibits growth hormone and IGF-1 secretion, reduces carcinoid syndrome mediators (urinary 5-HIAA), and suppresses various endocrine, neuroendocrine, exocrine, and paracrine functions.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Somavert